01 January 1999
Effect of probucol on plasma apolipoproteins C-III in Apo B- and non-Apo B - containing lipoproteins in patients with cardiovascular artery disease
Barbara Millo, Barbara Torbus-Lisiecka, Zdzisława Kornacewicz-Jach, Marek NaruszewiczMed Sci Monit 1999; 5(1): CR111-117 :: ID: 505270
Abstract
The distribution of apolipoproteins C-III (apo C-III) among lipoproteins may be causatively associated with cardiovascular artery disease (CAD). The objective of this study was to evaluate the changes in plasma concentration of lipids, lipoproteins and apolipoproteins in CAD patients, qualified for coronary by-pass surgery, before and after short-time administration of probucol. 19 patients (mean 53±12 years) with angiographically confirmed cardiovascular artery disease were treated with probucol (2x500 mg/day) for 3 weeks. Patients were evaluated before and after the drug administration. Levels of total apolipoproteins C-III (apo C-III) and apo C-III in plasma devoided of apo B-containig particles (apo C-III-nonLp-B) by immunoprecipitation using specific anti-apo B antiserum, were measured by electroimmunoassay. Apo C-III concentrations in apo B-containing lipoproteins (apo-C-III-LpB) were calculated by difference between total and apo C-III-nonLpB. Almost all lipid parameters significantly decreased after probucol therapy: total cholesterol from 254.8±40.1 to 213.3±44.5 mg/dl, LDL-cholesterol from 181.5±37.0 to 141±38.9 mg/dl, HDL from 40.0±5.3 to 33.6±5.5 mg/dl, triglycerides from 153.3±35.5 to 128.0±48.1mg/dl. Total apoC-III decreased from 27.3±7.2 to 23.2±8.5 mg/l, apo C-III-nonLpB from 18.8±6.8 to 13.2±5.1 mg/l, the apo C-III ratio (apo C-III-nonLp- B/apo C-III-Lp-B) changed from 2.55±1.56 to 1.47±0.63. The relationship between apo C-III, apo C-III-non- Lp-B, apo C-III-Lp-B and triglycerides remarkably changed after probucol therapy: r=0.41 (NS) vs. r=0.80 (p<0.001); r=0.42 (NS) vs. r=0.78 (p<0.001) and r=0.04 (NS) vs. r=0.55 (p<0.05), respectively. The different relationship was observed also between apo C-III-Lp-B and HDL3-cholesterol (r = -0.45, p<0.05 vs. r =-0.07, NS) Our results confirmed that probucol influences on lipid metabolism and apo C-III is involved in this process. Probucol decreased apo C-III mainly in lipoproteins without apo B, it was possible that probucol rearranged the action of apo-C-IIILpB.
Keywords: CAD, Probucol, Apolipoprotein C-III
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
07 Mar 2024 : Clinical Research
Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...Med Sci Monit In Press; DOI: 10.12659/MSM.943468
08 Mar 2024 : Animal Research
Modification of Experimental Model of Necrotizing Enterocolitis (NEC) in Rat Pups by Single Exposure to Hyp...Med Sci Monit In Press; DOI: 10.12659/MSM.943443
18 Apr 2024 : Clinical Research
Comparative Analysis of Open and Closed Sphincterotomy for the Treatment of Chronic Anal Fissure: Safety an...Med Sci Monit In Press; DOI: 10.12659/MSM.944127
08 Mar 2024 : Laboratory Research
Evaluation of Retentive Strength of 50 Endodontically-Treated Single-Rooted Mandibular Second Premolars Res...Med Sci Monit In Press; DOI: 10.12659/MSM.944110
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952